Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B7148

Sigma-Aldrich

Buspirone hydrochloride

≥99% (TLC), powder, 5-HT1A serotonin receptor agonist

Synonym(s):

N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

1 G
HUF 43,400.00
5 G
HUF 102,000.00

HUF 43,400.00

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
1 G
HUF 43,400.00
5 G
HUF 102,000.00

About This Item

Empirical Formula (Hill Notation):
C21H31N5O2 · HCl
CAS Number:
33386-08-2
Molecular Weight:
421.96
EC Number:
251-489-4
MDL number:
MFCD00078569
UNSPSC Code:
12352200
PubChem Substance ID:
24278079
NACRES:
NA.77

HUF 43,400.00

Please contact Customer Service for Availability
Request a Bulk Order

Product Name

Buspirone hydrochloride,

form

powder

Quality Level

100

originator

Bristol-Myers Squibb

storage temp.

2-8°C

SMILES string

Cl[H].O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4

InChI

1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H

InChI key

RICLFGYGYQXUFH-UHFFFAOYSA-N

Gene Information

human ... HTR1A(3350)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

5-HT1A serotonin receptor agonist; anxiolytic.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK4551
BCCG0755
BCCC9648
BCBZ3793
BCBW1483

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E Meller et al.
Molecular pharmacology, 37(2), 231-237 (1990-02-01)
The irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was used to determine the relationship between receptor occupancy and response at central 5-hydroxytryptamine1A (5-HT1A) serotonin receptors mediating the inhibition of serotonin synthesis in rat cortex and hippocampus. Rats were treated with vehicle or
G Tunnicliff
Pharmacology & toxicology, 69(3), 149-156 (1991-09-01)
Buspirone has been available in the United States for over four years for the treatment of anxiety. It was anticipated this drug would offer certain advantages over the established benzodiazepines. In contrast to diazepam, early studies found no evidence for
Taku Yamaguchi et al.
Journal of ethnopharmacology, 143(2), 533-539 (2012-07-24)
Yokukansan, a traditional Japanese medicine (Kampo), has been reported in the treatment of behavioral and psychological symptoms of dementia (BPSD) such as aggression, anxiety and depression in patients with Alzheimer's disease and other forms of senile dementia. In the present
Mohammad-Reza Mohammadi et al.
Acta medica Iranica, 50(11), 723-728 (2013-01-08)
A recent randomized clinical trial showed buspirone efficacy in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children. However, results from a recent multi-site controlled clinical trial of transdermal buspirone failed to separate it from placebo in a large sample of
Roy H Perlis et al.
The Journal of clinical psychiatry, 73(11), 1439-1442 (2012-10-13)
A subset of patients undergoing initial antidepressant treatment experience worsening of symptoms, including thoughts of suicide or suicidal behavior. The present study explores whether this subset of patients is also more likely to experience recurrence or worsening of these symptoms
View All Related Papers

Articles

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service